Giroctocogene fitelparvovec was being evaluated in a phase 3 study in men with moderately severe to severe hemophilia A (AFFINE; NCT04370054) [57], but the US Food and Drug Administration has placed this study on hold until proposed protocol amendments have been implemented, due to FVIII levels being >150% in some participants [57]. This evidence concerns the gene F8 and hemophilia A.